ReviewBioMed research international2018
Targeting CD36 as Biomarker for Metastasis Prognostic: How Far from Translation into Clinical Practice?
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 83 citations in OpenAlex.
- Article
- Very low-density lipoprotein and the human health.World journal of experimental medicine · 2026Review
- Exploring Lipid Metabolic Reprogramming: Mechanistic Insights and Implications for Tumor Radiotherapy.International journal of biological sciences · 2026Review
- Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications.Frontiers in cell and developmental biology · 2025Review
- Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment.NPJ precision oncology · 2024Article
- Expression of Anoikis-Related Genes and Potential Biomarkers in Colon Cancer Based on RNA-seq and scRNA-seq.Applied biochemistry and biotechnology · 2024Article
- Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.International journal of molecular sciences · 2024Review
- Melanoma-Derived Extracellular Vesicles Induce CD36-Mediated Pre-Metastatic Niche.Biomolecules · 2024Article
- First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.Communications medicine · 2024Article
- LncRNAs-circRNAs as Rising Epigenetic Binary Superstars in Regulating Lipid Metabolic Reprogramming of Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases.Cancers · 2023Article
- Deletion of CD36 exhibits limited impact on normal hematopoiesis and the leukemia microenvironment.Cellular & molecular biology letters · 2023Article
- Lipid Handling Protein Gene Expression in Colorectal Cancer: CD36 and Targeting miRNAs.Life (Basel, Switzerland) · 2022Article
- CD36-Fatty Acid-Mediated Metastasis via the Bidirectional Interactions of Cancer Cells and Macrophages.Cells · 2022Review
- The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment.International journal of molecular sciences · 2022Article
- Genome-wide expression reveals potential biomarkers in breast cancer bone metastasis.Journal of integrative bioinformatics · 2022Article
- Posttranslational control of lipogenesis in the tumor microenvironment.Journal of hematology & oncology · 2022Review
- Lipotoxicity as a Barrier for T Cell-Based Therapies.Biomolecules · 2022Review
- Lipid metabolism in tumor microenvironment: novel therapeutic targets.Cancer cell international · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis requires cellular changes related to cell-to-cell and cell-to-matrix adhesion, immune surveillance, activation of growth and survival signalling pathways, and epigenetic modifications. In addition to tumour cells, tumour stroma is also modified in relationship to the primary tumour as well as to distant metastatic sites (forming a metastatic niche). A common denominator of most stromal partners in tumour progression is CD36, a scavenger receptor for fatty acid uptake that modulates cell-to-extracellular matrix attachment, stromal cell fate (for adipocytes, endothelial cells), TGF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.